Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising.

• MindBio Therapeutics is developing AI-powered voice analysis technology designed to detect drug and alcohol impairment from short speech samples.
• The platform analyzes more than 140 acoustic markers and has been trained on a dataset exceeding 50 million data points.
• Mining operations in South America represent the company’s initial commercial focus, where workforce safety and high-volume screening requirements create operational challenges.
• Potential applications extend beyond mining into aviation, construction, law enforcement, call centers, transportation, and mental health settings.
• The global alcohol and drug testing devices market is projected to grow from approximately $2.5 billion in 2025 to $4.2 billion by 2033.
• MindBio’s approach seeks to provide a faster, less invasive alternative to traditional breath, saliva, urine and laboratory-based testing methods.

Workplace impairment testing remains an essential component of risk management across many industries, but the methods used today have changed relatively little over the past several decades. Employers continue to rely heavily on breathalyzers, saliva tests, urine screening and laboratory analysis to identify alcohol and drug impairment. While effective, these methods can be expensive, time-consuming and difficult to scale across large workforces. That challenge is becoming increasingly relevant as regulators and employers place greater emphasis on workplace safety, compliance and operational efficiency.

Against this backdrop, MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology company, is developing a technology platform that takes a different approach. The company has spent several years conducting drug and alcohol research while building artificial intelligence and machine-learning…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://nnw.fm/MBQIF

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Targets Growing Need for Non-Invasive Intoxication Detection.